These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 11754529)

  • 21. The FDA's regulatory role in the ICCVAM process.
    Schechtman LM; Stokes WS
    Altern Lab Anim; 2004 Jun; 32 Suppl 1B():663-8. PubMed ID: 23581155
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the skin sensitizing potential of unsaturated compounds as assessed by the murine local lymph node assay (LLNA) and the guinea pig maximization test (GPMT).
    Kreiling R; Hollnagel HM; Hareng L; Eigler D; Lee MS; Griem P; Dreessen B; Kleber M; Albrecht A; Garcia C; Wendel A
    Food Chem Toxicol; 2008 Jun; 46(6):1896-904. PubMed ID: 18343554
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Implementation of the 3Rs (refinement, reduction, and replacement): validation and regulatory acceptance considerations for alternative toxicological test methods.
    Schechtman LM
    ILAR J; 2002; 43 Suppl():S85-94. PubMed ID: 12388858
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A new path forward: the Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) and National Toxicology Program's Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM).
    Casey W; Jacobs A; Maull E; Matheson J; Clarke C; Lowit A
    J Am Assoc Lab Anim Sci; 2015 Mar; 54(2):170-3. PubMed ID: 25836963
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The local lymph node assay and the assessment of relative potency: status of validation.
    Basketter DA; Gerberick F; Kimber I
    Contact Dermatitis; 2007 Aug; 57(2):70-5. PubMed ID: 17627643
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Local lymph node assay: use in hazard and risk assessment.
    Dearman RJ; Basketter DA; Kimber I
    J Appl Toxicol; 1999; 19(5):299-306. PubMed ID: 10513674
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inter-laboratory validation of the modified murine local lymph node assay based on 5-bromo-2'-deoxyuridine incorporation.
    Kojima H; Takeyoshi M; Sozu T; Awogi T; Arima K; Idehara K; Ikarashi Y; Kanazawa Y; Maki E; Omori T; Yuasa A; Yoshimura I
    J Appl Toxicol; 2011 Jan; 31(1):63-74. PubMed ID: 20677212
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The local lymph node assay being too sensitive?
    Hans-Werner V; Jürgen AH
    Arch Toxicol; 2005 Dec; 79(12):721-8. PubMed ID: 16025312
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intra-laboratory study to determine the reproducibility of LLNA:BrdU-ELISA for the prediction of the skin sensitizing potential of chemicals.
    Chen W; Xing C; Hou F
    J Pharmacol Toxicol Methods; 2016; 82():26-30. PubMed ID: 27456929
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alternative methods to safety studies in experimental animals: role in the risk assessment of chemicals under the new European Chemicals Legislation (REACH).
    Lilienblum W; Dekant W; Foth H; Gebel T; Hengstler JG; Kahl R; Kramer PJ; Schweinfurth H; Wollin KM
    Arch Toxicol; 2008 Apr; 82(4):211-36. PubMed ID: 18322675
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Framework for metals risk assessment.
    Fairbrother A; Wenstel R; Sappington K; Wood W
    Ecotoxicol Environ Saf; 2007 Oct; 68(2):145-227. PubMed ID: 17889701
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Skin irritation and sensitization: mechanisms and new approaches for risk assessment.
    Basketter D; Darlenski R; Fluhr JW
    Skin Pharmacol Physiol; 2008; 21(4):191-202. PubMed ID: 18509253
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The local lymph node assay: current position in the regulatory classification of skin sensitizing chemicals.
    Basketter DA; Gerberick GF; Kimber I
    Cutan Ocul Toxicol; 2007; 26(4):293-301. PubMed ID: 18058304
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The impact of vehicle on the relative potency of skin-sensitizing chemicals in the local lymph node assay.
    Jowsey IR; Clapp CJ; Safford B; Gibbons BT; Basketter DA
    Cutan Ocul Toxicol; 2008; 27(2):67-75. PubMed ID: 18568891
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of the dog as non-rodent test species in the safety testing schedule associated with the registration of crop and plant protection products (pesticides): present status.
    Box RJ; Spielmann H
    Arch Toxicol; 2005 Nov; 79(11):615-26. PubMed ID: 15940470
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Validating new toxicology tests for regulatory acceptance.
    Zeiger E; Stokes WS
    Regul Toxicol Pharmacol; 1998 Feb; 27(1 Pt 1):32-7. PubMed ID: 9629594
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An European inter-laboratory validation of alternative endpoints of the murine local lymph node assay: 2nd round.
    Ehling G; Hecht M; Heusener A; Huesler J; Gamer AO; van Loveren H; Maurer T; Riecke K; Ullmann L; Ulrich P; Vandebriel R; Vohr HW
    Toxicology; 2005 Aug; 212(1):69-79. PubMed ID: 15878228
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Performance standards and alternative assays: practical insights from skin sensitization.
    Kolle SN; Basketter DA; Casati S; Stokes WS; Strickland J; van Ravenzwaay B; Vohr HW; Landsiedel R
    Regul Toxicol Pharmacol; 2013 Mar; 65(2):278-85. PubMed ID: 23279805
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.